Evaluation of human fetal neural stem/progenitor cells as a source for cell replacement therapy for neurological disorders: Properties and tumorigenicity after long-term in vitro maintenance

Daisuke Ogawa, Yohei Okada, Masaya Nakamura, Yonehiro Kanemura, Hirotaka James Okano, Yumi Matsuzaki, Takuya Shimazaki, Mamoru Ito, Eiji Ikeda, Takashi Tamiya, Seigo Nagao, Hideyuki Okano

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

It is expected that human neural stem/progenitor cells (hNS/PCs) will some day be used in cell replacement therapies. However, their availability is limited because of ethical issues, so they have to be expanded to obtain sufficient amounts for clinical application. Moreover, in-vitro-maintained hNS/PCs may have a potential for tumorigenicity that could be manifested after transplantation in vivo. In the present study, we demonstrate the in vitro and in vivo properties of long-term-expanded hNS/PCs, including a 6-month bioluminescence imaging (BLI) study of their in vivo tumorigenicity. hNS/PCs cultured for approximately 250 days in vitro (hNS/PCs-250) exhibited a higher growth rate and greater neurogenic potential than those cultured for approximately 500 days in vitro (hNS/PCs-500), which showed greater gliogenic potential. In vivo, both hNS/PCs-250 and -500 differentiated into neurons and astrocytes 4 weeks after being transplanted into the striatum of immunodeficient mice, and hNS/PCs-250 exhibited better survival than hNS/PCs-500 at this time point. We also found that the grafted hNS/PCs-250 survived stably and differentiated properly into neurons and astrocytes even 6 months after the surgery. Moreover, during the 6-month observation period by BLI, we did not detect any evidence of rapid tumorigenic growth of the grafted hNS/PCs, and neither PCNA/ Ki67-positive proliferating cells nor significant malignant invasive features were detected histologically. These findings support the idea that hNS/PCs may represent a nontumorigenic, safe, and appropriate cell source for regenerative therapies for neurological disorders.

Original languageEnglish
Pages (from-to)307-317
Number of pages11
JournalJournal of Neuroscience Research
Volume87
Issue number2
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Fetal Stem Cells
Neural Stem Cells
Cell- and Tissue-Based Therapy
Nervous System Diseases
Stem Cells
Maintenance
Astrocytes
In Vitro Techniques
Neurons
Proliferating Cell Nuclear Antigen
Growth
Ethics

Keywords

  • Immunodeficient mouse
  • In vivo optical imaging
  • Long-term cultures
  • Long-term engraftment
  • Neural stem cell

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Evaluation of human fetal neural stem/progenitor cells as a source for cell replacement therapy for neurological disorders : Properties and tumorigenicity after long-term in vitro maintenance. / Ogawa, Daisuke; Okada, Yohei; Nakamura, Masaya; Kanemura, Yonehiro; Okano, Hirotaka James; Matsuzaki, Yumi; Shimazaki, Takuya; Ito, Mamoru; Ikeda, Eiji; Tamiya, Takashi; Nagao, Seigo; Okano, Hideyuki.

In: Journal of Neuroscience Research, Vol. 87, No. 2, 01.02.2009, p. 307-317.

Research output: Contribution to journalArticle

Ogawa, Daisuke ; Okada, Yohei ; Nakamura, Masaya ; Kanemura, Yonehiro ; Okano, Hirotaka James ; Matsuzaki, Yumi ; Shimazaki, Takuya ; Ito, Mamoru ; Ikeda, Eiji ; Tamiya, Takashi ; Nagao, Seigo ; Okano, Hideyuki. / Evaluation of human fetal neural stem/progenitor cells as a source for cell replacement therapy for neurological disorders : Properties and tumorigenicity after long-term in vitro maintenance. In: Journal of Neuroscience Research. 2009 ; Vol. 87, No. 2. pp. 307-317.
@article{e6b72da51eae4606b25a166c17310cfc,
title = "Evaluation of human fetal neural stem/progenitor cells as a source for cell replacement therapy for neurological disorders: Properties and tumorigenicity after long-term in vitro maintenance",
abstract = "It is expected that human neural stem/progenitor cells (hNS/PCs) will some day be used in cell replacement therapies. However, their availability is limited because of ethical issues, so they have to be expanded to obtain sufficient amounts for clinical application. Moreover, in-vitro-maintained hNS/PCs may have a potential for tumorigenicity that could be manifested after transplantation in vivo. In the present study, we demonstrate the in vitro and in vivo properties of long-term-expanded hNS/PCs, including a 6-month bioluminescence imaging (BLI) study of their in vivo tumorigenicity. hNS/PCs cultured for approximately 250 days in vitro (hNS/PCs-250) exhibited a higher growth rate and greater neurogenic potential than those cultured for approximately 500 days in vitro (hNS/PCs-500), which showed greater gliogenic potential. In vivo, both hNS/PCs-250 and -500 differentiated into neurons and astrocytes 4 weeks after being transplanted into the striatum of immunodeficient mice, and hNS/PCs-250 exhibited better survival than hNS/PCs-500 at this time point. We also found that the grafted hNS/PCs-250 survived stably and differentiated properly into neurons and astrocytes even 6 months after the surgery. Moreover, during the 6-month observation period by BLI, we did not detect any evidence of rapid tumorigenic growth of the grafted hNS/PCs, and neither PCNA/ Ki67-positive proliferating cells nor significant malignant invasive features were detected histologically. These findings support the idea that hNS/PCs may represent a nontumorigenic, safe, and appropriate cell source for regenerative therapies for neurological disorders.",
keywords = "Immunodeficient mouse, In vivo optical imaging, Long-term cultures, Long-term engraftment, Neural stem cell",
author = "Daisuke Ogawa and Yohei Okada and Masaya Nakamura and Yonehiro Kanemura and Okano, {Hirotaka James} and Yumi Matsuzaki and Takuya Shimazaki and Mamoru Ito and Eiji Ikeda and Takashi Tamiya and Seigo Nagao and Hideyuki Okano",
year = "2009",
month = "2",
day = "1",
doi = "10.1002/jnr.21843",
language = "English",
volume = "87",
pages = "307--317",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Evaluation of human fetal neural stem/progenitor cells as a source for cell replacement therapy for neurological disorders

T2 - Properties and tumorigenicity after long-term in vitro maintenance

AU - Ogawa, Daisuke

AU - Okada, Yohei

AU - Nakamura, Masaya

AU - Kanemura, Yonehiro

AU - Okano, Hirotaka James

AU - Matsuzaki, Yumi

AU - Shimazaki, Takuya

AU - Ito, Mamoru

AU - Ikeda, Eiji

AU - Tamiya, Takashi

AU - Nagao, Seigo

AU - Okano, Hideyuki

PY - 2009/2/1

Y1 - 2009/2/1

N2 - It is expected that human neural stem/progenitor cells (hNS/PCs) will some day be used in cell replacement therapies. However, their availability is limited because of ethical issues, so they have to be expanded to obtain sufficient amounts for clinical application. Moreover, in-vitro-maintained hNS/PCs may have a potential for tumorigenicity that could be manifested after transplantation in vivo. In the present study, we demonstrate the in vitro and in vivo properties of long-term-expanded hNS/PCs, including a 6-month bioluminescence imaging (BLI) study of their in vivo tumorigenicity. hNS/PCs cultured for approximately 250 days in vitro (hNS/PCs-250) exhibited a higher growth rate and greater neurogenic potential than those cultured for approximately 500 days in vitro (hNS/PCs-500), which showed greater gliogenic potential. In vivo, both hNS/PCs-250 and -500 differentiated into neurons and astrocytes 4 weeks after being transplanted into the striatum of immunodeficient mice, and hNS/PCs-250 exhibited better survival than hNS/PCs-500 at this time point. We also found that the grafted hNS/PCs-250 survived stably and differentiated properly into neurons and astrocytes even 6 months after the surgery. Moreover, during the 6-month observation period by BLI, we did not detect any evidence of rapid tumorigenic growth of the grafted hNS/PCs, and neither PCNA/ Ki67-positive proliferating cells nor significant malignant invasive features were detected histologically. These findings support the idea that hNS/PCs may represent a nontumorigenic, safe, and appropriate cell source for regenerative therapies for neurological disorders.

AB - It is expected that human neural stem/progenitor cells (hNS/PCs) will some day be used in cell replacement therapies. However, their availability is limited because of ethical issues, so they have to be expanded to obtain sufficient amounts for clinical application. Moreover, in-vitro-maintained hNS/PCs may have a potential for tumorigenicity that could be manifested after transplantation in vivo. In the present study, we demonstrate the in vitro and in vivo properties of long-term-expanded hNS/PCs, including a 6-month bioluminescence imaging (BLI) study of their in vivo tumorigenicity. hNS/PCs cultured for approximately 250 days in vitro (hNS/PCs-250) exhibited a higher growth rate and greater neurogenic potential than those cultured for approximately 500 days in vitro (hNS/PCs-500), which showed greater gliogenic potential. In vivo, both hNS/PCs-250 and -500 differentiated into neurons and astrocytes 4 weeks after being transplanted into the striatum of immunodeficient mice, and hNS/PCs-250 exhibited better survival than hNS/PCs-500 at this time point. We also found that the grafted hNS/PCs-250 survived stably and differentiated properly into neurons and astrocytes even 6 months after the surgery. Moreover, during the 6-month observation period by BLI, we did not detect any evidence of rapid tumorigenic growth of the grafted hNS/PCs, and neither PCNA/ Ki67-positive proliferating cells nor significant malignant invasive features were detected histologically. These findings support the idea that hNS/PCs may represent a nontumorigenic, safe, and appropriate cell source for regenerative therapies for neurological disorders.

KW - Immunodeficient mouse

KW - In vivo optical imaging

KW - Long-term cultures

KW - Long-term engraftment

KW - Neural stem cell

UR - http://www.scopus.com/inward/record.url?scp=62849097510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849097510&partnerID=8YFLogxK

U2 - 10.1002/jnr.21843

DO - 10.1002/jnr.21843

M3 - Article

C2 - 18972448

AN - SCOPUS:62849097510

VL - 87

SP - 307

EP - 317

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 2

ER -